LFG
SUPN icon

Larson Financial Group’s Supernus Pharmaceuticals SUPN Stock Holding History

Larson Financial Group’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.98K Hold
150
– – ﹤0.01% 2614
2026
Q1 		$7.75K Hold
150
– – ﹤0.01% 2381
2025
Q4 		$7.46K Buy
+150
New +$7.29K ﹤0.01% 2282
2025
Q3 		– Sell
-5
Closed -$158 – 3637
2025
Q2 		$158 Hold
5
– – ﹤0.01% 3102
2025
Q1 		$164 Hold
5
– – ﹤0.01% 2830
2024
Q4 		$181 Hold
5
– – ﹤0.01% 2468
2024
Q3 		$156 Hold
5
– – ﹤0.01% 2442
2024
Q2 		$134 Buy
+5
New +$145 ﹤0.01% 2188

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Larson Financial Group's SUPN Position: Q2 2026 in Review

Larson Financial Group held its Supernus Pharmaceuticals (SUPN) position steady in Q2 2026 at 150 shares worth $6.98K. The position accounts for ﹤0.01% of the portfolio, ranked #2614.

Larson Financial Group first reported a position in SUPN in Q2 2024 and has held it in 8 quarters since. The position peaked at $7.75K in Q1 2026. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Larson Financial Group held 150 shares of Supernus Pharmaceuticals worth $6.98K as of Q2 2026.
  • Larson Financial Group left its Supernus Pharmaceuticals share count unchanged in Q2 2026.
  • Supernus Pharmaceuticals made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #2614 holding.
  • Larson Financial Group first reported a position in Supernus Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
  • Larson Financial Group's Supernus Pharmaceuticals position peaked at $7.75K in Q1 2026.
  • 332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.